South Dakotamed spa & injectable regulations
What’s changing for med spas and injectors in South Dakota — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in South Dakota. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Latest South Dakota changes
No South Dakota-specific changes have crossed our radar yet — we’re actively monitoring the South Dakota legislature and licensing boards. The federal changes below apply to every South Dakota practice today.
Federal changes that apply in South Dakota
FDA and Federal Register actions are nationwide — they govern South Dakota practices too.
- CRITICALFEDERALFDA Enforcement2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
- CRITICALFEDERALFDA Enforcement2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product; check your stock now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies!
- CRITICALFEDERALFDA Enforcement2026-03-11
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
FDA recalls Semaglutide for sterility issues—act now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
FDA recalls Wegovy due to safety concerns; med spas must act.
- CRITICALFEDERALFDA Enforcement2025-07-02
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
FDA recalls GLP-1 product over sterility issues.
What we monitor in South Dakota
- South Dakota legislature — bills on injectables, GLP-1s & scope of practice
- South Dakota Board of Nursing — injector scope & delegation
- South Dakota Medical Board — physician supervision & ownership rules
- South Dakota Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
South Dakota med spa compliance — FAQ
- Where do South Dakota med spa and injectable regulations come from?
- South Dakota med spas and injectors are governed by a mix of state and federal authorities — the South Dakota legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for South Dakota and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in South Dakota?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in South Dakota. We track those federal changes alongside any South Dakota-specific rules so you see the full picture for your practice.
- How do I keep up with South Dakota regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across South Dakota, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Never miss a South Dakota change
Get the free weekly Brief on what changed across South Dakota, the FDA, and the Federal Register. Members get the exact what-to-do, in real time, for their states.
Get the free Brief →← All states · Regulatory monitoring, not legal advice.